[go: up one dir, main page]

HUE059387T2 - Parkinson-kór kezelése - Google Patents

Parkinson-kór kezelése

Info

Publication number
HUE059387T2
HUE059387T2 HUE17743097A HUE17743097A HUE059387T2 HU E059387 T2 HUE059387 T2 HU E059387T2 HU E17743097 A HUE17743097 A HU E17743097A HU E17743097 A HUE17743097 A HU E17743097A HU E059387 T2 HUE059387 T2 HU E059387T2
Authority
HU
Hungary
Prior art keywords
parkinson
disease
treatment
Prior art date
Application number
HUE17743097A
Other languages
English (en)
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji Mandhane
Manoj Atmaramji Upadhya
Sameer Vishwanath Mehetre
Gajanan Uttamrao Chidrewar
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of HUE059387T2 publication Critical patent/HUE059387T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE17743097A 2016-06-02 2017-06-02 Parkinson-kór kezelése HUE059387T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
IN201621019185 2016-06-02

Publications (1)

Publication Number Publication Date
HUE059387T2 true HUE059387T2 (hu) 2022-11-28

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17743097A HUE059387T2 (hu) 2016-06-02 2017-06-02 Parkinson-kór kezelése

Country Status (26)

Country Link
US (4) US10849887B2 (hu)
EP (2) EP3463351B1 (hu)
JP (1) JP6974357B2 (hu)
KR (1) KR102508288B1 (hu)
CN (1) CN109475539B (hu)
AU (1) AU2017273415B2 (hu)
CA (1) CA3024976A1 (hu)
CL (1) CL2018003431A1 (hu)
CY (1) CY1125285T1 (hu)
DK (1) DK3463351T3 (hu)
ES (1) ES2914782T3 (hu)
HR (1) HRP20220683T1 (hu)
HU (1) HUE059387T2 (hu)
IL (1) IL263188B (hu)
LT (1) LT3463351T (hu)
MX (1) MX385276B (hu)
MY (1) MY193754A (hu)
PH (1) PH12018502457B1 (hu)
PL (1) PL3463351T3 (hu)
PT (1) PT3463351T (hu)
RS (1) RS63243B1 (hu)
SG (1) SG11201810294QA (hu)
SI (1) SI3463351T1 (hu)
SM (1) SMT202200228T1 (hu)
UA (1) UA123018C2 (hu)
WO (1) WO2017208267A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2844256B1 (en) 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
WO2017208267A1 (en) 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
CA3120639A1 (en) 2018-11-20 2020-05-28 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
MA56179A (fr) * 2019-06-11 2022-04-20 Sun Pharma Advanced Res Co Ltd Traitement de synucléinopathies
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
US20230301982A1 (en) 2020-07-31 2023-09-28 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of alzheimer's disease
CN119562810A (zh) 2022-05-02 2025-03-04 太阳医药高级研究有限公司 用于减少帕金森氏病进展的沃多巴替尼
WO2025058473A1 (ko) 2023-09-14 2025-03-20 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012098416A1 (en) * 2011-01-21 2012-07-26 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
EP2844256B1 (en) 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
BR112017024633A2 (pt) 2015-05-18 2018-07-31 Sun Pharma Advanced Research Company Limited novo amidoeteroaril aroil hidrazida etino
WO2017208267A1 (en) * 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease

Also Published As

Publication number Publication date
CN109475539A (zh) 2019-03-15
US20210015805A1 (en) 2021-01-21
RS63243B1 (sr) 2022-06-30
ES2914782T3 (es) 2022-06-16
EP3463351A1 (en) 2019-04-10
JP6974357B2 (ja) 2021-12-01
LT3463351T (lt) 2022-06-10
KR20190015257A (ko) 2019-02-13
CY1125285T1 (el) 2025-03-28
US20220273632A1 (en) 2022-09-01
HRP20220683T1 (hr) 2022-07-08
AU2017273415B2 (en) 2023-01-19
KR102508288B1 (ko) 2023-03-09
CA3024976A1 (en) 2017-12-07
PH12018502457A1 (en) 2019-10-21
US11813252B2 (en) 2023-11-14
BR112018074439A2 (pt) 2019-03-06
EP4085912A1 (en) 2022-11-09
MX385276B (es) 2025-03-18
CL2018003431A1 (es) 2019-05-10
IL263188B (en) 2021-08-31
DK3463351T3 (da) 2022-06-07
PL3463351T3 (pl) 2022-06-20
US11583522B2 (en) 2023-02-21
US10849887B2 (en) 2020-12-01
SI3463351T1 (sl) 2022-07-29
IL263188A (en) 2018-12-31
AU2017273415A1 (en) 2018-12-06
JP2019520344A (ja) 2019-07-18
US20240066014A1 (en) 2024-02-29
PT3463351T (pt) 2022-06-02
SMT202200228T1 (it) 2022-07-21
CN109475539B (zh) 2021-12-28
US20190275017A1 (en) 2019-09-12
UA123018C2 (uk) 2021-02-03
MY193754A (en) 2022-10-27
WO2017208267A1 (en) 2017-12-07
PH12018502457B1 (en) 2022-01-12
EP3463351B1 (en) 2022-04-27
MX2018014944A (es) 2019-03-07
SG11201810294QA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
EP3562514A4 (en) GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE
LT3463351T (lt) Parkinsono ligos gydymas
DK3364997T5 (da) Aspartoacylase genterapi til behandling af canavans sygdom
IL247085B (en) Methods for treating Alzheimer's disease
DK2968218T3 (da) Kombination til behandling af parkinsons sygdom
ZA201605341B (en) Methods of treating alzheimer's disease
EP3487507A4 (en) VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
EP3448263A4 (en) Electrotherapeutic treatment
DK3548061T3 (da) Behandling af neurologiske sygdomme
IL270900A (en) Treatment of cutaneous disorders
PT3458045T (pt) Ebselen para uso no tratamento da doença de ménière
SMT202100177T1 (it) Trattamento di disturbi neutologici
EP3474876A4 (en) TREATMENT OF MORBUS CANAVAN
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
LT3148588T (lt) N,n-bis-2-merkaptoetilizoftalamidas, skirtas parkinsono ligos gydymui
GB201622116D0 (en) Treatment of liver disease
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
IL263837A (en) Treatment of ocular disease
ZA201807944B (en) Treatment for parkinson's disease
MA45177A (fr) Traitement de la maladie de parkinson
GB201504144D0 (en) Treatment of Parkinson's disease
GB201621398D0 (en) Treatment of emt-associated disease
GB201511453D0 (en) Treatment of alzheimer's disease